This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Feb;18(2):233-4.

doi: 10.1038/mt.2009.314.

Oncolytic viruses: an approved product on the horizon?

PMID: 20125160
PMCID: PMC2839306
DOI: 10.1038/mt.2009.314

Editorial

Oncolytic viruses: an approved product on the horizon?

John Bell. Mol Ther. 2010 Feb.

. 2010 Feb;18(2):233-4.

doi: 10.1038/mt.2009.314.

Author

PMID: 20125160
PMCID: PMC2839306
DOI: 10.1038/mt.2009.314

No abstract available

PubMed Disclaimer

Similar articles

Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies.
Yamaguchi T, Uchida E. Yamaguchi T, et al. Curr Cancer Drug Targets. 2018;18(2):202-208. doi: 10.2174/1568009617666170222142650. Curr Cancer Drug Targets. 2018. PMID: 28228083 Review.
Regulatory aspects of oncolytic virus products.
Yamaguchi T, Uchida E. Yamaguchi T, et al. Curr Cancer Drug Targets. 2007 Mar;7(2):203-8. doi: 10.2174/156800907780058790. Curr Cancer Drug Targets. 2007. PMID: 17346112 Review.
Clinical development of oncolytic viruses in China.
Liang M. Liang M. Curr Pharm Biotechnol. 2012 Jul;13(9):1852-7. doi: 10.2174/138920112800958760. Curr Pharm Biotechnol. 2012. PMID: 21740357 Review.
Oncorine, the World First Oncolytic Virus Medicine and its Update in China.
Liang M. Liang M. Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503. Curr Cancer Drug Targets. 2018. PMID: 29189159 Review.
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S, Fukuhara H, Todo T. Taguchi S, et al. Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170. Jpn J Clin Oncol. 2019. PMID: 30462296 Review.

See all similar articles

Cited by

Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR, van Eijck CH, Hofland LJ, Fouchier RA, van den Hoogen BG. Buijs PR, et al. Cancer Gene Ther. 2014 Jan;21(1):24-30. doi: 10.1038/cgt.2013.78. Epub 2014 Jan 3. Cancer Gene Ther. 2014. PMID: 24384773
Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.
Buijs PR, van Amerongen G, van Nieuwkoop S, Bestebroer TM, van Run PR, Kuiken T, Fouchier RA, van Eijck CH, van den Hoogen BG. Buijs PR, et al. Cancer Gene Ther. 2014 Nov;21(11):463-71. doi: 10.1038/cgt.2014.51. Epub 2014 Sep 26. Cancer Gene Ther. 2014. PMID: 25257305
Oncogenic Ras inhibits IRF1 to promote viral oncolysis.
Komatsu Y, Christian SL, Ho N, Pongnopparat T, Licursi M, Hirasawa K. Komatsu Y, et al. Oncogene. 2015 Jul 23;34(30):3985-93. doi: 10.1038/onc.2014.331. Epub 2014 Oct 27. Oncogene. 2015. PMID: 25347735
Reovirus: a targeted therapeutic--progress and potential.
Maitra R, Ghalib MH, Goel S. Maitra R, et al. Mol Cancer Res. 2012 Dec;10(12):1514-25. doi: 10.1158/1541-7786.MCR-12-0157. Epub 2012 Oct 4. Mol Cancer Res. 2012. PMID: 23038811 Free PMC article. Review.
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
Leveille S, Goulet ML, Lichty BD, Hiscott J. Leveille S, et al. J Virol. 2011 Dec;85(23):12160-9. doi: 10.1128/JVI.05703-11. Epub 2011 Sep 14. J Virol. 2011. PMID: 21917977 Free PMC article.

See all "Cited by" articles

References

1. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23:209–214. - PubMed
1. Bartee E., and , McFadden G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-β. Cytokine. 2009;47:199–205. - PMC - PubMed
1. Power AT., and , Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 2007;15:660–665. - PubMed
1. Ivy P, Wick JY., and , Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6 - PubMed
1. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database